PHM Pharma Mar, S.A.

BME · ES · Healthcare · Biotechnology · pharmamar.com

70.00EUR-1.48%Mkt Cap: 1.32B $P/E: 23.26Today

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, res…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap1.32B USD

Enterprise Value1.21B USD

Revenue (TTM)237.66M USD

Gross Profit227.32M USD

Net Income (TTM)81.51M USD

Revenue/Share12.13 EUR

Last Price70.00 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees505

CountryES

SectorHealthcare

IndustryBiotechnology

ISINES0169501022

Valuation

P/E (Trailing)23.26

P/E (Forward)10.89

PEG0.31

EV/EBITDA24.87

EV/Revenue5.10

P/S5.65

P/B4.94

EPS (TTM)3.01

EPS (Forward)6.56

52W Range

64.0015% of range105.20

52W High105.20 EUR

52W Low64.00 EUR

Profitability

Gross Margin94.46%

Oper. Margin-2.83%

EBITDA Margin20.50%

Profit Margin33.87%

ROE29.78%

ROA18.98%

Growth

Revenue Growth-12.00%

Earnings Growth—

Cash Flow & Leverage

Operating CF57.75M USD

CapEx (TTM)10.19M USD

FCF Margin18.75%

FCF Yield3.39%

Net Debt-133.74M USD

Net Debt/EBITDA-2.74

Balance Sheet

Debt/Equity0.20

Current Ratio2.85

Quick Ratio2.20

Book Value/Sh14.47 EUR

Cash/Share9.74 EUR

Dividends

Fwd Div Rate1.00 EUR

Trail. Div Rate1.00 EUR

Div. Yield1.40%

5Y Avg Yield1.13%

Payout Ratio0.00%

Ex-Div DateJul 8, 2026

Pay Date—

Splits

Last Split1:12

Split DateJul 22, 2020

Analyst Consensus

Rating1.6 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)102.94 EUR

Upside (mean)+47.1%

Target Range85.50 EUR – 125.00 EUR

85.50+47.1% to mean125.00

# Analysts8

Ownership

Shares Out.17.29M

Float13.40M

Insiders27.21%

Institutions10.33%

Technical

SMA 5078.97 (-11.4%)

SMA 20082.87 (-15.5%)

Beta0.43

S&P 52W Chg14.58%

Avg Vol (30d)21.27K

Avg Vol (10d)24.84K

Technical Indicators

RSI (14)28.6

MACD-2.2807

MACD Signal-1.9933

MACD Hist.-0.2874

BB Upper80.82 EUR

BB Middle75.19 EUR

BB Lower69.55 EUR

BB Width14.99%

ATR (14)1.919 EUR

Vol Ratio (20d)0.89x